Experts worry FDA’s credibility is being shredded by scandal and ‘soap opera’

Taking stock of the drug industry, from the lab to the medicine chest

November 4, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Photo illustration: STAT; Photo: Adobe STAT+ | Experts worry FDA's credibility is being shredded by scandal and 'soap opera' Lawsuit against Tidmarsh latest blow to agency whose credibility has been shredded by infighting, regulatory uncertainty. "Nothing less than a clown show." By Matthew Herper and Lizzy Lawrence STAT+ | Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly Trump drug price negotiations expected to include Medicare coverage for weight loss drugs Wegovy, Zepbound, and prices as low as $150 By Daniel Payne, Elaine Chen, and Chelsea Cirruzzo STAT+ | Compass Pathways expects earlier FDA approval decision on its psilocybin drug The company plans a rolling submission of data on the depression therapy after a "positive" meeting with agency. By Elaine Chen Molly Ferguson/STAT STAT+ | Sarepta Therapeutics' dismal quarter marred by drug failures and a long list of excuses A long-delayed confirmatory clinical trial fails to show a benefit for patients, and sales of the company's Elevidys gene therapy were lower. By Adam Feuerstein STAT+ | Jennifer Doudna spinoff aims to turn patients' immune cells into CAR-T fighters with single shot Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer fighters with a single shot. By Jason Mast and Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser